A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Fasinumab (Primary)
- Indications Back pain; Osteoarthritis; Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT CLBP 1
- Sponsors Regeneron Pharmaceuticals
- 14 Nov 2019 This trial has been Discontinued in United Kingdom, according to European Clinical Trials Database record.
- 20 May 2019 Status changed from active, no longer recruiting to completed.
- 18 Apr 2019 This trial has been Discontinued in Hungary, according to European Clinical Trials Database.